期刊文献+

介入治疗、三维适形放疗与氩氦刀治疗原发性肝癌的临床对比研究 被引量:2

Clinical study on interventional therapy,three-dimensional conformal radiotherapy and targeted argon-helium cryoablation to primary hepatocellular carcinoma
下载PDF
导出
摘要 目的将介入治疗、三维适形放疗和氩氦靶向冷冻消融治疗(氩氦刀治疗)三种方法结合比较,探讨不适合手术的原发性肝癌患者的较好治疗方案。方法将符合入选的116例原发性肝癌患者分为单纯介入组(A组)、介入+三维适形放疗(3DCRT)组(B组)和介入+氩氦刀组(C组),比较三组的生存情况。结果 (1)A组、B组和C组1年生存率分别是14.98%、64%、85.71%;2年生存率分别是11.24%、32%、64.29%;3年生存率分别是0、0、32.14%。(2)三组间生存函数曲线差异有显著性(P<0.05),C组的生存曲线较A组和B组好。结论介入+氩氦刀治疗能延长患者的生存时间,是不适合手术的原发性肝癌患者的较好治疗方案。 Objective To find out a better therapy for unresectable HCC on the basis of the survival time by using three methods compared which were interventional therapy(IVT),three-dimensional conformal radiotherapy(3D-CRT),and targeted argon-helium cryoablation therapy(AHC).Methods Total of 116 patients with unresectable HCC were divided into three groups which were IVT group(A group),the IVT and 3D-CRT group(B group) and the IVT and AHC group(C group).Results The survival rates for 1 year in A,B and C group were 14.98%,64.00%,85.71%,respectively.The corresponding survival rates for 2 year were 11.24%,32%,64.29%,respectively.The corresponding survival rates for 3 year were 0,0,32.14%,respectively.2.There were significantly different of survival functions in three groups(P0.05).The survival curves of C group were better than that of A group and B group.Conclusion The IVT and ACH are a suitable therapy with unresectable HCC because of increased survival time of the patients.
出处 《贵州医药》 CAS 2010年第8期687-690,共4页 Guizhou Medical Journal
关键词 原发性肝癌 肝动脉灌注化疗 肝动脉化疗栓塞 三维适形放射治疗 氩氦靶向冷冻消融治疗 生存时间 Hepatocellular carcinoma(HCC) Transcatheter arterial infusion transcatheter arterial chemoembolization Three-dimensional conformal radiotherapy targeted argon-helium cryoablation therapy Survival time
  • 相关文献

参考文献13

  • 1Lau WY,Thomas WT,Leung,et al.Percutaneous local ablative therapy for hepatoeellular carcinoma[J].Annals of Surgery,2003,237:171-179.
  • 2原发性肝癌的临床诊断与分期标准[J].肝脏,2004,9(S1):67-68. 被引量:52
  • 3Alsowmely AM,Hodgson HJF.Non-surgical treatment of hepatocellular carcinoma[J].Aliment Pharmacol Ther,2002,16:1-15.
  • 4Douglas E,Ramsey AB,Lily Y,et al.Chemoembolization of Hepatocellular Carcinoma[J].J Vasc Interv Radiol,2002,13:211-221.
  • 5Transarterial chemoembolization(TACE)for unresectable hepatocellular carcinoma in cirrhotics:functional hepatic reserve and survival[J].Hepatogastroenterology,2003,50(49):207-212.
  • 6Huang YH,Chen CH,Chang TT,et al.The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma:a nationwide,multicentre study evaluated by cancer stage[J].Aliment Pharmacol Ther,2005,21(6):687-694.
  • 7李玉,闫英,张海波,郭占文,严子才,李东.适形放射治疗结合介入治疗不宜手术的原发性肝癌[J].中华放射肿瘤学杂志,2003,12(1):30-32. 被引量:94
  • 8Yamada K,Izaki K,Sugimoto K,et al.Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma[J].Iht J Radiat Oncol Biol Phys,2003,57:113-119.
  • 9Dawson LA,Normolle D,Baiter JM.Analysis of radiation-induced liver disease using the Lyman NTCP model[J].Int J Radiat Oncol Biol Phys,2002,53(4):810-821.
  • 10Dawson LA,Ten Haken RK,Lawrence TS.Partial irradiation of the liver[R].Semin Radiat Oncol,2001,11(3):240-246.

二级参考文献9

共引文献177

同被引文献13

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部